WO2014071218A3 - Biomarkers for breast cancer and methods of using same - Google Patents

Biomarkers for breast cancer and methods of using same Download PDF

Info

Publication number
WO2014071218A3
WO2014071218A3 PCT/US2013/068117 US2013068117W WO2014071218A3 WO 2014071218 A3 WO2014071218 A3 WO 2014071218A3 US 2013068117 W US2013068117 W US 2013068117W WO 2014071218 A3 WO2014071218 A3 WO 2014071218A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
breast cancer
biomarkers
same
inhibitor
Prior art date
Application number
PCT/US2013/068117
Other languages
French (fr)
Other versions
WO2014071218A2 (en
Inventor
Stephanie CUNHA
Alana Lee WELM
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Publication of WO2014071218A2 publication Critical patent/WO2014071218A2/en
Publication of WO2014071218A3 publication Critical patent/WO2014071218A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are methods of treating breast cancer. Further provided are methods and kits for assessing the likelihood that breast cancer in a subject will metastasize or has metastasized. Further provided are methods and kits for determining whether a subject having breast cancer would benefit from treatment with at least one of a RON inhibitor and a PI3K kinase inhibitor. Further provided are methods of monitoring a molecular response of a subject to treatment of breast cancer with at least one of a RON inhibitor and a PI3K inhibitor.
PCT/US2013/068117 2012-11-02 2013-11-01 Biomarkers for breast cancer and methods of using same WO2014071218A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261721977P 2012-11-02 2012-11-02
US61/721,977 2012-11-02
US201361851796P 2013-03-13 2013-03-13
US61/851,796 2013-03-13

Publications (2)

Publication Number Publication Date
WO2014071218A2 WO2014071218A2 (en) 2014-05-08
WO2014071218A3 true WO2014071218A3 (en) 2015-07-16

Family

ID=50628258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/068117 WO2014071218A2 (en) 2012-11-02 2013-11-01 Biomarkers for breast cancer and methods of using same

Country Status (1)

Country Link
WO (1) WO2014071218A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101833983B1 (en) * 2016-02-23 2018-03-02 순천대학교 산학협력단 Composition for predicting prognosis of cancer, kit comprising the same and uses thereof
WO2020248018A1 (en) * 2019-06-14 2020-12-17 Children's Medical Research Institute Methods of treating cancer with an inhibitor of znf827
EP4013494A1 (en) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
CN111549117B (en) * 2020-05-21 2023-03-31 天津医科大学总医院 Biomarker and application thereof in Parkinson
CN113604571A (en) * 2021-09-02 2021-11-05 北京大学第一医院 Gene combination for human tumor classification and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170084A1 (en) * 2007-02-02 2009-07-02 Orion Genomics Llc Gene methylation in breast cancer
US20100131432A1 (en) * 2008-11-17 2010-05-27 Kennedy Giulia C Methods and compositions of molecular profiling for disease diagnostics
US20110145176A1 (en) * 2008-05-30 2011-06-16 Perou Charles M Gene expression profiles to predict breast cancer outcomes
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy
WO2012112645A1 (en) * 2011-02-17 2012-08-23 Trustees Of Dartmouth College Markers for identifying breast cancer treatment modalities

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170084A1 (en) * 2007-02-02 2009-07-02 Orion Genomics Llc Gene methylation in breast cancer
US20110145176A1 (en) * 2008-05-30 2011-06-16 Perou Charles M Gene expression profiles to predict breast cancer outcomes
US20100131432A1 (en) * 2008-11-17 2010-05-27 Kennedy Giulia C Methods and compositions of molecular profiling for disease diagnostics
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy
WO2012112645A1 (en) * 2011-02-17 2012-08-23 Trustees Of Dartmouth College Markers for identifying breast cancer treatment modalities

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU ET AL.: "Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase'.", GENES & CANCER., vol. 2, no. 7, July 2011 (2011-07-01), pages 753 - 762 *
PRINZ ET AL.: "Elimination of breast tumor-associated chondroitin sulfate promotes metastasis.", GENETICS AND MOLECULAR RESEARCH, vol. 10, no. ISSUE, 8 December 2011 (2011-12-08), pages 3901 - 3913 *

Also Published As

Publication number Publication date
WO2014071218A2 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
IL254062B (en) Kits comprising anti-ptk7 antibody and use thereof in treating, detecting, diagnosing, or monitoring cancer
MX2017008421A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder.
WO2014150751A3 (en) Biomarkers associated with brm inhibition
EP2524059A4 (en) Detection of gastrointestinal disorders
MX2020008976A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
MX2017010836A (en) Biomarker panel for the detection of cancer.
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX2013001293A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity.
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
HK1218313A1 (en) Methods and kits for the molecular subtyping of tumors
WO2013163568A3 (en) Methods for evaluating lung cancer status
MA39776A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2014071218A3 (en) Biomarkers for breast cancer and methods of using same
MX2015015605A (en) Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2015070001A3 (en) Compositions and methods for detecting and/or treating inflammation
WO2012109632A3 (en) Crown-like structures as a biomarker for cancer risk and cancer prognosis
BR112015020054A2 (en) METHOD OF DETECTING RESISTANCE TO THE THERAPEUTIC EFFECTS OF AN AKT INHIBITOR IN A CANCER CELL
PL2959021T3 (en) Methods and kits for the molecular subtyping of tumors
WO2014072832A8 (en) Biomarkers for cervical cancer
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
WO2012166824A3 (en) Methods and kits that identify tumors responsive to src inhibitors
EP3591050A3 (en) Use of rhoa in cancer diagnosis and inhibitor screening

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13850707

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13850707

Country of ref document: EP

Kind code of ref document: A2